Lakefront Biotherapeutics (GXEA) AI Stock Analysis

Company Guidance

Guidance for 2026 centers on the planned close of the Ouro transaction in Q2 and the related cash outlook: the company expects to incur EUR 60–75m of Ouro-related cash expenditures (operating costs and transaction expenses) in 2026 and, together with an upfront payment of ~EUR 713m, to spend EUR 775–790m total on Ouro in 2026. Management also expects one‑time cash costs of EUR 125–175m to wind down cell therapy activities, and inclusive of Ouro and the wind‑down now forecasts year‑end cash and cash equivalents of EUR 1.975–2.05 billion. For context, cash and financial investments were EUR 2,982.2m on March 31, 2026 (versus EUR 3,297m on March 31, 2025), Q1 revenues were EUR 6.5m (EUR 4.9m supply revenue, EUR 1.6m collaboration revenue) versus EUR 75m in Q1 2025, R&D was EUR 31m, operating loss improved to EUR 63.7m (vs. EUR 158.7m a year ago, which included EUR 111m restructuring), net financial income was EUR 77.7m (including ~EUR 64.3m unrealized FX gains) driving a Q1 net profit of EUR 14.5m (vs. a EUR 153.4m loss in Q1 2025). The company also highlighted that the revised OLCA terms unlock a EUR 500m commitment for broader use (up to EUR 150m of which may be used for return of capital), received shareholder approval for a share repurchase program, and said it will retain a majority of its cash after estimated R&D spend on gamgertamig through first approval.